Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab plus chemotherapy as neoadjuvant treatment in locally advanced unresectable pancreatic cancer
2019-001925-28Phase 3Completed
- Sponsor
- FibroGen
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing Pamrevlumab + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: Overall survival. Started Dec 2019; status: completed.
02
Drugs
pamrevlumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2019-001925-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001925-28.